EUVIMEDEUVIMED entdecken
Open Access

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study

Subbaramireddy Remala iD, Liming Liang iD, Amil M Shah iD, Leo F Buckley iD

Circulation: Genomic and Precision Medicine · 2026

DOI: 10.1161/circgen.125.005535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, 2026. Verfasst von Subbaramireddy Remala und 3 weiteren Autor:innen. Beteiligte Einrichtung: Translational Cardiovascular Epidemiology Research Unit, Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Me…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors and GLP-1R (glucagon-like peptide-1 receptor) agonists reduce the risk of major adverse cardiovascular and kidney events in individuals with various cardiometabolic conditions. The long-term efficacy and safety of these therapies, especially in low- and moderate-risk populations, remain uncertain. METHODS: We conducted a biobank-scale analysis using genetic instruments derived from naturally occurring genetic variations in the genes encoding the targets of SGLT2 inhibitors (SLC5A2) and GLP-1R agonists (GLP1R) that are associated with glycated hemoglobin levels. This Mendelian randomization study utilized data from the All of Us Research Program, which includes whole genome sequencing and electronic health records of 633 547 participants. RESULTS: Higher SGLT2 inhibitor genetic instrument scores were associated with a lower risk of heart failure (odds ratio [OR], 0.97 [95% CI, 0.96–0.99]) and chronic kidney disease (OR, 0.98 [95% CI, 0.96–0.99]). Higher GLP-1R agonist genetic instrument scores were linked to reduced risks of heart failure (OR, 0.97 [95% CI, 0.96–0.99]), chronic kidney disease (OR, 0.96 [95% CI, 0.95–0.98]), and coronary artery disease (OR, 0.98 [95% CI, 0.96–0.99]). We did not detect associations between the GLP-1R agonist instrument and multiple endocrine neoplasia or medullary thyroid carcinoma. PheWAS (Phenome-Wide Association Study) identified associations between the SGLT2 inhibitor and GLP-1R agonist genetic instruments and a lower risk of diabetes, but no other phenotypes. CONCLUSIONS: This study demonstrates the utility of biobank-scale health data for pharmacology research and suggests that, if feasible to implement in routine practice, long-term, primary prevention with an SGLT2 inhibitor or GLP-1R agonist would safely lower the risk of major adverse cardiovascular and kidney events in low- to moderate-risk adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2HumansMendelian Randomization AnalysisGlucagon-Like Peptide-1 ReceptorFemaleMaleSodium-Glucose Transporter 2

Stichwörter der Autor:innen

glucagon-like peptide-1 receptorheart failurepharmacogenomic testingprimary preventionsodium-glucose transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorGLP1R protein, humanSLC5A2 protein, humanSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Translational Cardiovascular Epidemiology Research Unit, Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (S.R., A.M.S., L.F.B.).
  • Department of Epidemiology, TH Chan School of Public Health, Harvard University, Boston, MA (L.L.).

ORCID-Profile: Subbaramireddy Remala, Liming Liang, Amil M Shah, Leo F Buckley

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Remala, S., Liang, L., Shah, A. M., & Buckley, L. F. (2026). Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.125.005535

Vancouver

Remala S, Liang L, Shah AM, Buckley LF. Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study. Circulation: Genomic and Precision Medicine. 2026. doi:10.1161/circgen.125.005535

BibTeX
@article{Remala2026,
  author = {Remala, Subbaramireddy and Liang, Liming and Shah, Amil M and Buckley, Leo F},
  title = {Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study},
  journal = {Circulation: Genomic and Precision Medicine},
  year = {2026},
  doi = {10.1161/circgen.125.005535}
}
Kostenlos starten →